http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2286339-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-08 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C275-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-41 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-36 |
| filingDate | 2002-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af05d374f18dd1254e04a9b2f8ed0579 |
| publicationDate | 2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2286339-C2 |
| titleOfInvention | Derivatives of 1,2-diaminopentane as antagonists of ccr-3 receptors and pharmaceutical composition based on thereof |
| abstract | FIELD: organic chemistry, medicine, pharmacy. n SUBSTANCE: invention relates to derivatives of 1,2-diaminopentane of the formula (I): wherein R 1 means hydrogen atom, (C 1 -C 6 )-alkyl; R 2 means phenyl-(C 1 -C 6 )-alkyl wherein phenyl is substituted with halogen atom; R 3 means hydrogen atom; R 4 means -W-X-Y-Z wherein W is absent or means (C 1 -C 6 )-alkylene; X is absent or means -S(O) n - or -N(R a )-; Y means arylene or heteroarylene; Z means hydrogen atom, aryl; R a means hydrogen atom; n = 0 under condition that this enumeration doesn't involve trans-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]benzamide and trans-N-methyl-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]benzamide, or its pharmaceutically acceptable salt. Also, invention proposes a pharmaceutical composition possessing antagonistic activity with respect to CCR-3 receptors and comprising the effective amount of compound of the formula (I) or its salt and excipient. Invention provides using derivatives of 1,2-diaminopentane inhibiting binding eotaxine with CCR-3 receptors. n EFFECT: valuable medicinal properties of compounds and pharmaceutical composition. n 27 cl, 1 tbl, 17 ex |
| priorityDate | 2001-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 207.